[1] RUDIN C M, BRAMBILLA E, FAIVRE-FINN C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021,7(1):3.
[2] ABDEL-RAHMAN O. Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis[J]. Clin Respir J, 2018,12(3):1093-1099.
[3] WANG P, LI C, AN Y, at al. The management of elderly patients with lung cancer: a single center retrospective study[J]. Ann Palliat Med, 2021,10(1):229-237.
[4] WANG S, ZIMMERMANN S, PARIKH K, at al. Current diagnosis and management of small-cell lung cancer[J]. Mayo Clin Proc, 2019, 94(8):1599-1622.
[5] LIU S V, RECK M, MANSFIELD A S, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39(6):619-630.
[6] GOLDMAN J W, DVORKIN M, CHEN Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(1):51-65.
[7] SAMANI A, ZHANG S, SPIERS L, et al. Impact of age on the toxicity of immune checkpoint inhibition[J]. J Immunother Cancer, 2020, 8(2):e000871. |
